O	0	7	Effects
O	8	10	of
O	11	14	the
O	15	23	ACTIVity
O	24	27	And
O	28	38	TEchnology
O	39	40	(
O	40	48	ACTIVATE
O	48	49	)
O	50	62	intervention
O	63	65	on
O	66	72	health
O	72	73	-
O	73	80	related
O	81	88	quality
O	89	91	of
O	92	96	life
O	97	100	and
O	101	108	fatigue
O	109	117	outcomes
O	118	120	in
O	121	127	breast
O	128	134	cancer
O	135	144	survivors
O	144	145	.

O	146	149	The
O	150	158	ACTIVATE
O	159	164	Trial
O	165	173	examined
O	174	177	the
O	178	186	efficacy
O	187	189	of
O	190	191	a
B-intervention	192	200	wearable
I-intervention	200	201	-
I-intervention	201	206	based
I-intervention	207	219	intervention
O	220	222	to
O	223	231	increase
O	232	240	physical
O	241	249	activity
O	250	253	and
O	254	260	reduce
O	261	270	sedentary
O	271	279	behavior
O	280	282	in
O	283	289	breast
O	290	296	cancer
O	297	306	survivors
O	306	307	.

O	308	312	This
O	313	318	paper
O	319	327	examines
O	328	331	the
O	332	339	effects
O	340	342	of
O	343	346	the
O	347	359	intervention
O	360	362	on
O	363	369	health
O	369	370	-
O	370	377	related
O	378	385	quality
O	386	388	of
O	389	393	life
O	394	395	(
O	395	400	HRQoL
O	400	401	)
O	402	405	and
O	406	413	fatigue
O	414	416	at
O	417	419	12
O	420	425	weeks
O	426	427	(
O	427	429	T2
O	429	430	;
O	431	434	end
O	435	437	of
O	438	450	intervention
O	450	451	)
O	452	455	and
O	456	458	24
O	459	464	weeks
O	465	466	(
O	466	468	T3
O	468	469	;
O	470	476	follow
O	476	477	-
O	477	479	up
O	479	480	)
O	480	481	.

B-eligibility	482	490	Inactive
I-eligibility	491	494	and
I-eligibility	495	509	postmenopausal
I-eligibility	510	515	women
I-eligibility	516	519	who
I-eligibility	520	523	had
I-eligibility	524	533	completed
I-eligibility	534	541	primary
I-eligibility	542	551	treatment
I-eligibility	552	555	for
I-eligibility	556	561	stage
I-eligibility	562	563	I
I-eligibility	563	564	-
I-eligibility	564	567	III
I-eligibility	568	574	breast
I-eligibility	575	581	cancer
O	582	586	were
O	587	597	randomized
O	598	600	to
O	601	613	intervention
O	614	616	or
B-control	617	625	waitlist
I-control	626	633	control
O	633	634	.

O	635	643	Physical
O	644	652	activity
O	653	656	and
O	657	666	sedentary
O	667	675	behavior
O	676	680	were
O	681	689	measured
O	690	692	by
O	693	702	Actigraph
O	703	706	and
O	707	715	activPAL
O	716	730	accelerometers
O	731	733	at
O	734	742	baseline
O	743	744	(
O	744	746	T1
O	746	747	)
O	747	748	,
O	749	752	end
O	753	755	of
O	756	759	the
O	760	772	intervention
O	773	774	(
O	774	776	T2
O	776	777	)
O	777	778	,
O	779	782	and
O	783	785	12
O	786	791	weeks
O	792	798	follow
O	798	799	-
O	799	801	up
O	802	803	(
O	803	805	T3
O	805	806	)
O	806	807	.

O	808	813	HRQoL
O	814	817	and
O	818	825	fatigue
O	826	830	were
O	831	839	measured
O	840	845	using
O	846	849	the
O	850	860	Functional
O	861	871	Assessment
O	872	874	of
O	875	881	Cancer
O	882	889	Therapy
O	889	890	-
O	890	896	Breast
O	897	898	(
O	898	902	FACT
O	902	903	-
O	903	904	B
O	904	905	)
O	906	909	and
O	910	913	the
O	914	924	Functional
O	925	935	Assessment
O	936	938	of
O	939	946	Chronic
O	947	954	Illness
O	955	962	Therapy
O	962	963	-
O	963	970	Fatigue
O	971	972	(
O	972	977	FACIT
O	977	978	-
O	978	985	Fatigue
O	985	986	)
O	986	987	.

O	988	995	Primary
O	996	1008	intervention
O	1009	1016	effects
O	1017	1021	were
O	1022	1031	evaluated
O	1032	1041	comparing
O	1042	1054	intervention
O	1055	1058	and
O	1059	1067	waitlist
O	1068	1073	group
O	1074	1076	at
O	1077	1079	T2
O	1080	1085	using
O	1086	1094	repeated
O	1095	1103	measures
O	1104	1109	mixed
O	1110	1117	effects
O	1118	1124	models
O	1124	1125	.

O	1126	1133	Overall
O	1133	1134	,
B-total-participants	1135	1137	83
O	1138	1143	women
O	1144	1148	were
O	1149	1159	randomized
O	1160	1163	and
O	1164	1169	trial
O	1170	1179	retention
O	1180	1183	was
O	1184	1188	high
O	1189	1190	(
O	1190	1192	94
O	1192	1193	%
O	1193	1194	)
O	1194	1195	.

O	1196	1197	A
O	1198	1199	4
O	1199	1200	.
O	1200	1201	6
O	1201	1202	-
O	1202	1207	point
O	1208	1218	difference
O	1219	1221	in
B-outcome	1222	1229	fatigue
I-outcome	1230	1235	score
O	1236	1239	was
O	1240	1248	observed
O	1249	1256	between
O	1257	1263	groups
O	1264	1266	at
O	1267	1269	T2
O	1270	1271	(
O	1271	1273	95
O	1273	1274	%
O	1275	1277	CI
O	1277	1278	:
O	1279	1280	1
O	1280	1281	.
O	1281	1282	3
O	1282	1283	,
O	1284	1285	7
O	1285	1286	.
O	1286	1287	8
O	1287	1288	)
O	1289	1299	indicating
O	1300	1311	improvement
O	1312	1314	in
O	1315	1322	fatigue
O	1323	1331	profiles
O	1332	1334	in
O	1335	1338	the
O	1339	1351	intervention
O	1352	1357	group
O	1357	1358	.

O	1359	1361	In
O	1362	1368	within
O	1369	1375	groups
O	1376	1384	analyses
O	1384	1385	,
O	1386	1389	the
O	1390	1402	intervention
O	1403	1408	group
O	1409	1417	reported
O	1418	1419	a
B-iv-cont-mean	1420	1421	5
I-iv-cont-mean	1421	1422	.
I-iv-cont-mean	1422	1423	1
I-iv-cont-mean	1423	1424	-
I-iv-cont-mean	1424	1429	point
O	1430	1438	increase
O	1439	1441	in
B-outcome	1442	1449	fatigue
I-outcome	1450	1454	from
I-outcome	1455	1463	baseline
I-outcome	1464	1466	to
I-outcome	1467	1469	T2
O	1470	1471	(
O	1471	1473	95
O	1473	1474	%
O	1475	1477	CI
O	1477	1478	:
O	1479	1480	2
O	1480	1481	.
O	1481	1482	0
O	1482	1483	,
O	1484	1485	8
O	1485	1486	.
O	1486	1487	2
O	1487	1488	)
O	1489	1492	and
O	1493	1494	a
B-cv-cont-mean	1495	1496	3
I-cv-cont-mean	1496	1497	.
I-cv-cont-mean	1497	1498	3
I-cv-cont-mean	1498	1499	-
I-cv-cont-mean	1499	1504	point
O	1505	1513	increase
B-outcome	1514	1518	from
I-outcome	1519	1527	baseline
I-outcome	1528	1530	to
I-outcome	1531	1533	T3
O	1534	1535	(
O	1535	1537	95
O	1537	1538	%
O	1539	1541	CI
O	1541	1542	:
O	1543	1544	0
O	1544	1545	.
O	1545	1546	1
O	1546	1547	,
O	1548	1549	6
O	1549	1550	.
O	1550	1552	41
O	1552	1553	)
O	1553	1554	.

O	1555	1562	Despite
O	1563	1568	small
O	1569	1581	improvements
O	1582	1584	in
O	1585	1592	fatigue
O	1593	1601	profiles
O	1601	1602	,
O	1603	1605	no
O	1606	1613	effects
O	1614	1616	on
B-outcome	1617	1622	HRQoL
O	1623	1627	were
O	1628	1636	observed
O	1636	1637	.

O	1638	1643	While
O	1644	1647	the
O	1648	1656	ACTIVATE
O	1657	1662	Trial
O	1663	1666	was
O	1667	1677	associated
O	1678	1682	with
O	1683	1695	improvements
O	1696	1698	in
O	1699	1707	physical
O	1708	1716	activity
O	1717	1720	and
O	1721	1730	sedentary
O	1731	1739	behavior
O	1739	1740	,
O	1741	1745	more
O	1746	1755	intensive
O	1756	1758	or
O	1759	1765	longer
O	1766	1774	duration
O	1775	1788	interventions
O	1789	1792	may
O	1793	1795	be
O	1796	1802	needed
O	1803	1805	to
O	1806	1816	facilitate
O	1817	1824	changes
O	1825	1827	in
O	1828	1833	HRQoL
O	1833	1834	.
